The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphomaMike I. Walton, Michelle D. Garrett|Oncotarget|2015Cited by 69